ArticleThoracic cancer2025
Diagnostic Value of Photon-Counting CT in Pericardial Metastases: A Single-Center Retrospective Study.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic Value of Photon-Counting CT in Pericardial Metastases: A Single-Center Retrospective Study.Thoracic cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pericardial metastases are common in advanced cancers but often remain undetected due to subtle symptoms. Photon-counting CT (PCT) offers improved spatial resolution and contrast-to-noise ratio (CNR) compared with conventional CT (CCT), potentially enhancing diagnostic performance. In this retrospective single-center study, patients diagnosed with pericardial metastases by transthoracic echocardiography (TTE) between April and September 2025, who underwent both unenhanced and contrast-enhanced chest CT were included. After Propensity Score Matching (PSM), two groups were established: the PCT group (n = 11; reconstructions at 0.4 and 1 mm) and the CCT group (n = 22). Diagnostic sensitivity, image quality, and radiation dose were assessed, with TTE as the reference standard. PCT-0.4 mm demonstrated the highest overall sensitivity (91.5%) and small-lesion sensitivity (88.9%), followed by PCT-1 mm (87.2% and 83.3%) and CCT-1 mm (86.1% and 78.6%). Although not statistically significant, PCT showed consistently better lesion detection. The PCT-0.4 mm group showed higher standardized CNR versus CCT-1 mm (Tukey-Kramer p = 0.021) but not versus PCT-1 mm (p = 0.641); overall one-way ANOVA p = 0.020, whereas SNR did not differ among groups (ANOVA p = 0.18). Radiation exposure was significantly lower with PCT than CCT (ED: 11.7 ± 3.9 vs. 20.6 ± 6.6 mSv; p < 0.001). Compared with the 1-mm CCT reconstruction, the 0.4-mm PCT showed a trend toward improved detection of both overall and small pericardial metastases, enhanced image quality, and reduced radiation dose, highlighting its potential clinical value in managing pericardial metastases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.